CS
OLMA icon

Candriam SCA’s Olema Pharmaceuticals OLMA Stock Holding History

Candriam SCA’s Portfolio OLMA Stock Details OLMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.39M Sell
751,133
-8,380
-1% -$112K 0.04% 294
2026
Q1 		$11.3M Buy
759,513
+80,029
+12% +$1.78M 0.06% 261
2025
Q4 		$17M Sell
679,484
-570,243
-46% -$10.1M 0.08% 207
2025
Q3 		$12.2M Buy
1,249,727
+399,273
+47% +$2.4M 0.06% 248
2025
Q2 		$3.62M Sell
850,454
-63
-0% -$281 0.02% 406
2025
Q1 		$3.2M Sell
850,517
-701,045
-45% -$3.53M 0.02% 414
2024
Q4 		$9.05M Buy
1,551,562
+44,798
+3% +$447K 0.05% 277
2024
Q3 		$18M Buy
1,506,764
+448,091
+42% +$5.73M 0.1% 196
2024
Q2 		$11.5M Buy
1,058,673
+705,655
+200% +$7.65M 0.07% 238
2024
Q1 		$4M Buy
353,018
+138,010
+64% +$1.78M 0.03% 381
2023
Q4 		$3.02M Buy
+215,008
New +$2.89M 0.02% 418
2022
Q1 		– Sell
-332,572
Closed -$3.11M – 838
2021
Q4 		$3.11M Sell
332,572
-10,000
-3% -$207K 0.02% 458
2021
Q3 		$9.44M Sell
342,572
-7,000
-2% -$189K 0.06% 285
2021
Q2 		$9.78M Buy
349,572
+349,559
+2,688,915% +$9.95M 0.07% 289
2021
Q1 		$0 Buy
+13
New +$557 ﹤0.01% 817

Other funds holding OLMA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

Candriam SCA's OLMA Position: Q2 2026 in Review

Candriam SCA reduced its Olema Pharmaceuticals (OLMA) stake by 1.1% in Q2 2026, selling an estimated $112K and leaving 751,133 shares worth $9.39M. The position accounts for 0.04% of the portfolio, ranked #294.

Candriam SCA first reported a position in OLMA in Q1 2021 and has held it in 15 quarters since. The position peaked at $18M in Q3 2024. 186 funds tracked by Wall St. Rank hold OLMA as of Q2 2026.

  • Candriam SCA held 751,133 shares of Olema Pharmaceuticals worth $9.39M as of Q2 2026.
  • Candriam SCA sold 8,380 Olema Pharmaceuticals shares in Q2 2026, an estimated $112K.
  • Olema Pharmaceuticals made up 0.04% of Candriam SCA's portfolio in Q2 2026, its #294 holding.
  • Candriam SCA first reported a position in Olema Pharmaceuticals in Q1 2021 and has held it in 15 quarters since.
  • Candriam SCA's Olema Pharmaceuticals position peaked at $18M in Q3 2024.
  • 186 funds tracked by Wall St. Rank held Olema Pharmaceuticals as of Q2 2026.

Based on Candriam SCA's 13F filing for Q2 2026, filed 13 Aug 2026.